PH12008501738B1 - Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents - Google Patents

Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents

Info

Publication number
PH12008501738B1
PH12008501738B1 PH12008501738A PH12008501738A PH12008501738B1 PH 12008501738 B1 PH12008501738 B1 PH 12008501738B1 PH 12008501738 A PH12008501738 A PH 12008501738A PH 12008501738 A PH12008501738 A PH 12008501738A PH 12008501738 B1 PH12008501738 B1 PH 12008501738B1
Authority
PH
Philippines
Prior art keywords
benzoxazines
compounds useful
modulating agents
mineralocorticoid receptor
receptor modulating
Prior art date
Application number
PH12008501738A
Other languages
English (en)
Inventor
T Iijima
Y Yamamoto
H Akatsuka
T Kawaguchi
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of PH12008501738B1 publication Critical patent/PH12008501738B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/141,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/161,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
PH12008501738A 2006-02-02 2008-07-29 Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents PH12008501738B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006025403 2006-02-02
JP2006275917 2006-10-10

Publications (1)

Publication Number Publication Date
PH12008501738B1 true PH12008501738B1 (en) 2013-11-29

Family

ID=38110055

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12008501738A PH12008501738B1 (en) 2006-02-02 2008-07-29 Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents

Country Status (16)

Country Link
US (2) US7998956B2 (es)
EP (1) EP1984345B9 (es)
KR (1) KR101046548B1 (es)
AR (1) AR059280A1 (es)
AT (1) ATE522511T1 (es)
AU (1) AU2007210424C1 (es)
BR (1) BRPI0707491B8 (es)
CA (1) CA2636985C (es)
DK (1) DK1984345T3 (es)
MX (1) MX285869B (es)
PH (1) PH12008501738B1 (es)
PL (1) PL1984345T3 (es)
PT (1) PT1984345E (es)
RU (1) RU2398769C2 (es)
TW (1) TWI385161B (es)
WO (1) WO2007089034A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2125735B1 (en) * 2007-02-28 2012-06-27 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
US8258131B2 (en) * 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
MX2010010366A (es) 2008-03-31 2010-11-30 C & C Res Lab Derivados heterociclicos.
US20090253693A1 (en) * 2008-04-07 2009-10-08 Dmitry Koltun 2H-BENZO[b][1,4]OXAZIN-3(4H)-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
JO3398B1 (ar) 2011-12-22 2019-10-20 Novartis Ag مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
WO2013134518A1 (en) 2012-03-09 2013-09-12 Amgen Inc. Sulfamide sodium channel inhibitors
JP6014144B2 (ja) 2012-08-08 2016-10-25 田辺三菱製薬株式会社 1,4−ベンゾオキサジン化合物の製法
US9212182B2 (en) 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
EP3071203B1 (en) 2013-11-18 2020-12-23 Forma Therapeutics, Inc. Tetrahydroquinoline compositions as bet bromodomain inhibitors
WO2015074081A1 (en) 2013-11-18 2015-05-21 Bair Kenneth W Benzopiperazine compositions as bet bromodomain inhibitors
CN103694137A (zh) * 2013-12-06 2014-04-02 常州工程职业技术学院 一种2-氟-4-硝基苯甲腈的清洁生产方法
AU2015282450C1 (en) 2014-06-30 2018-09-20 Astrazeneca Ab Benzoxazinone amides as mineralocorticoid receptor modulators
EP3362095B1 (en) 2015-10-13 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
TWI603962B (zh) 2016-09-10 2017-11-01 國立清華大學 含硫噁嗪化合物及其合成方法
US11285160B2 (en) 2016-09-27 2022-03-29 Mitsubishi Tanabe Pharma Corporation Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
CA3039735A1 (en) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Combination containing sgc activators and mineralocorticoid receptor antagonists
CN110022871A (zh) 2016-10-11 2019-07-16 拜耳制药股份公司 包含sGC刺激物和盐皮质激素受体拮抗剂的组合产品
WO2018149754A1 (en) 2017-02-16 2018-08-23 Basf Se Pyridine compounds
WO2018153898A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten
DE102017008472A1 (de) 2017-09-08 2018-05-03 Bayer Pharma Aktiengesellschaft Kombination enthaltend PDE5 Inhibitoren und Mineralocorticoid-Rezeptor-Antagonisten
TW202045184A (zh) 2019-02-05 2020-12-16 日商田邊三菱製藥股份有限公司 預防或治療肺纖維化的藥物
JPWO2021107029A1 (es) 2019-11-26 2021-06-03
EP4118235A1 (en) 2020-03-11 2023-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224941B (es) 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
US5420126A (en) 1989-11-08 1995-05-30 Yamanouchi Pharmaceutical Co., Ltd. 3,4-dihydro-2H-1,4-benzoxazine derivatives and pharmaceutical compositions containing the same
CN1029479C (zh) 1989-11-08 1995-08-09 山之内制药株式会社 新型苯并噁嗪衍生物的制备方法
US5696117A (en) 1995-11-07 1997-12-09 Ortho Pharmaceutical Corporation Benzoxazine antimicrobial agents
DE19727117A1 (de) 1997-06-26 1999-01-07 Boehringer Ingelheim Pharma Phenylalkylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6358948B1 (en) * 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6498154B1 (en) * 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
AU2001236606A1 (en) * 2000-02-01 2001-08-14 Cor Therapeutics, Inc. 3,4-dihydro-2h-benzo(1,4)oxazine inhibitors of factor xa
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CN1742007A (zh) * 2003-01-22 2006-03-01 伊莱利利公司 甾族激素核受体的吲哚衍生物调控剂
CN1918151A (zh) 2003-12-19 2007-02-21 伊莱利利公司 三环甾类激素核受体调节剂
JP2007230869A (ja) 2004-04-05 2007-09-13 Takeda Chem Ind Ltd アルドステロン受容体拮抗剤
EP1844768A1 (en) * 2005-01-19 2007-10-17 Dainippon Sumitomo Pharma Co., Ltd. Aromatic sulfone compound as aldosterone receptor modulator

Also Published As

Publication number Publication date
CA2636985A1 (en) 2007-08-09
BRPI0707491A2 (pt) 2011-05-03
DK1984345T3 (da) 2011-12-12
KR101046548B1 (ko) 2011-07-05
TW200800926A (en) 2008-01-01
AU2007210424B2 (en) 2010-07-15
US7998956B2 (en) 2011-08-16
US20090023716A1 (en) 2009-01-22
AU2007210424C1 (en) 2010-11-18
US20110251185A1 (en) 2011-10-13
PL1984345T3 (pl) 2012-01-31
AR059280A1 (es) 2008-03-19
WO2007089034A1 (en) 2007-08-09
EP1984345B9 (en) 2012-03-21
MX285869B (en) 2011-04-19
RU2398769C2 (ru) 2010-09-10
CA2636985C (en) 2011-08-16
TWI385161B (zh) 2013-02-11
US8188073B2 (en) 2012-05-29
BRPI0707491B8 (pt) 2021-05-25
ATE522511T1 (de) 2011-09-15
EP1984345A1 (en) 2008-10-29
AU2007210424A1 (en) 2007-08-09
RU2008135468A (ru) 2010-03-10
KR20080083698A (ko) 2008-09-18
PT1984345E (pt) 2011-09-08
EP1984345B1 (en) 2011-08-31
BRPI0707491B1 (pt) 2019-12-10

Similar Documents

Publication Publication Date Title
PH12008501738B1 (en) Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents
IL183665A0 (en) Heterocyclic compounds as ccr2b antagonists
ZA200806392B (en) Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as SIP receptor agonists
HK1167397A1 (zh) 作為抗癌症劑的 -取代的喹唑酮衍生物
EP2155818A4 (en) COMPOSITIONS SUITABLE FOR USE AS GROUNDING COMPOUNDS AND ASSOCIATED METHODS
HK1147674A1 (en) Heterocyclic compounds as crth2 receptor antagonists crth2
IL198241A0 (en) Pyrazoline compounds as mineralocorticoid receptor antagonists
EP2188271A4 (en) HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
IL194815A0 (en) Fused heterocyclic compounds and their use as mglur5 modulators
IL195158A0 (en) Novel heterocyclic compounds
HK1115125A1 (en) 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
EP1991200A4 (en) FLUORCHINOLONZUSAMMENSETZUNGEN
IL199971A0 (en) Heterocyclic derivatives as m3 muscarinic receptors
EP2025671A4 (en) NITROGENIC HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
EP2065439A4 (en) polyolefin
EP2039695A4 (en) BICYCLIC HETEROCYLIC COMPOUND AND ITS USE
ZA200705159B (en) Heterocyclic compounds as CCR2B antagonists
EP2258676A4 (en) STABLE VINAMIDINIUM SALT AND USE THEREOF IN THE SYNTHESIS OF NITROGENIC HETEROCYCLIC CYCLES
IL189463A0 (en) Non-steroidal compounds useful as glucocorticoid receptor modulators
ZA200704979B (en) 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
GB0619308D0 (en) Heterocyclic compounds
IL173733A0 (en) Microbial compositions useful for the degradation of hydrocarbons
GB0624212D0 (en) Heterobicyclic, nitrogen-containing compounds
ZA200809385B (en) Novel heterocyclic compounds
RS56117B1 (sr) Derivati 5-supstituisanog hinazolinona kao antikancer agensi